EBGLYSS 250 mg/2mL (Lebrikizumab-Lbkz INJECTION, SOLUTION) 250 mg/2mL

EBGLYSS 250 mg/2mL is a subcutaneous injection solution containing lebrikizumab-lbkz. This medication is used to manage moderate-to-severe atopic dermatitis, providing targeted relief for skin inflammation. Learn more about EBGLYSS and its uses.

Strength

250 mg/2mL

Pack Size

2 SYRINGE in 1 CARTON (0002-7772-62) / 2 mL in 1 SYRINGE

Manufacturer / TM Owner

Eli Lilly and Company

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

EBGLYSS 250 mg/2mL is primarily used for the treatment of moderate-to-severe atopic dermatitis in adults and children. This condition is characterized by persistent skin inflammation and itching. The active ingredient, lebrikizumab-lbkz, works by targeting specific pathways involved in the inflammatory process. Patients often seek EBGLYSS for its potential to reduce symptoms and improve skin condition over time.

Side Effects

Common effects of EBGLYSS 250 mg/2mL may include redness, itching, or swelling at the injection site. Some users might experience mild to moderate skin reactions. These effects are generally temporary and should be monitored. If severe or persistent, consult a healthcare provider.

Precautions & Warnings

EBGLYSS 250 mg/2mL should be stored at room temperature and protected from light. Always use a new syringe for each injection to prevent contamination. Patients with a history of severe allergic reactions to lebrikizumab-lbkz or any of the ingredients should avoid using this medication. Follow the prescribed administration guidelines to ensure safety.

Avoid Interactions

EBGLYSS 250 mg/2mL may interact with other medications, including immunosuppressants and biologic therapies. Alcohol consumption should be avoided as it may exacerbate side effects. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

EBGLYSS 250 mg/2mL is used to treat moderate-to-severe atopic dermatitis, helping to reduce skin inflammation and itching.

EBGLYSS 250 mg/2mL is administered subcutaneously using the provided syringes. Follow the instructions provided by your healthcare provider.

Common side effects include redness, itching, or swelling at the injection site. Severe reactions are rare but should be reported to a healthcare provider.

EBGLYSS 250 mg/2mL may interact with other medications, so it's important to consult your healthcare provider before combining treatments.

Store EBGLYSS 250 mg/2mL at room temperature and protect it from light. Always use a new syringe for each injection.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.